Dromostanolone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, dromostanolone binds to the androgen receptor. This causes downstream genetic transcriptional changes. This ultimately causes retention of nitrogen, potassium, and phosphorus; increases protein anabolism; and decreases amino acid catabolism. The antitumour activity of dromostanolone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production.
Since estrogen is not an issue, side effects are generally mild with this steroid. As discussed earlier, gynecomastia, water retention, and high blood pressureare not a problem. Masteron is also not liver toxic, so there is little concern stress will be placed on this organ, even during longer cycles. The only real side effects would be from the basic androgenic properties of dihydrotestosterone. These includes oily skin, acne, body/facial hair growth, aggression and accelerated hair loss. Since this compound is already a synthetic DHT, Proscar would have no impact on the level of androgenic effects. Men with a receding hairline or those with a predisposition for baldness may therefore wish to stay away from Masteron completely, as the potent androgenic effect of this steroid can easily accelerate this condition.
However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use . In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months.